Paolo Ruzza1, Barbara Biondi, Andrea Calderan. 1. Institute of Biomolecular Chemistry of CNR, Padova Unit, c/o Dept. Chemical Sciences, University of Padova, via Marzolo 1, Padua, Italy. paolo.ruzza@unipd.it
Abstract
BACKGROUND: The non-receptor spleen tyrosine kinase (Syk; EC 2.7.10.2) is involved in signal transduction in a variety of cell types. In particular, it is a key mediator of immune receptors signaling in host inflammatory cells (B cells, mast cells, macrophages and neutrophils), important for both allergic and antibody-mediated autoimmune diseases. Deregulated Syk kinase activity also allows growth factor-independent proliferation and transforms bone marrow-derived pre-B cells that are able to induce leukemia. Consequently, the development of Syk kinase inhibitors could conceivably treat these disorders and so they have became a major focus in the pharmaceutical and biotech industry. OBJECTIVE: In this review, we analyze the structure and role of Syk kinase, the use of small molecules, interacting with ATP-binding site, as inhibitors of kinase activity and finally the potential of using inhibitors of Syk kinase expression to attenuate pathological conditions. CONCLUSION: Syk kinase inhibition is suggested as a powerful tool for the therapy of different pathologies.
BACKGROUND: The non-receptor spleen tyrosine kinase (Syk; EC 2.7.10.2) is involved in signal transduction in a variety of cell types. In particular, it is a key mediator of immune receptors signaling in host inflammatory cells (B cells, mast cells, macrophages and neutrophils), important for both allergic and antibody-mediated autoimmune diseases. Deregulated Syk kinase activity also allows growth factor-independent proliferation and transforms bone marrow-derived pre-B cells that are able to induce leukemia. Consequently, the development of Syk kinase inhibitors could conceivably treat these disorders and so they have became a major focus in the pharmaceutical and biotech industry. OBJECTIVE: In this review, we analyze the structure and role of Syk kinase, the use of small molecules, interacting with ATP-binding site, as inhibitors of kinase activity and finally the potential of using inhibitors of Syk kinase expression to attenuate pathological conditions. CONCLUSION:Syk kinase inhibition is suggested as a powerful tool for the therapy of different pathologies.
Authors: Omer Nuri Pamuk; Peter H Lapchak; Poonam Rani; Polly Pine; Jurandir J Dalle Lucca; George C Tsokos Journal: Am J Physiol Gastrointest Liver Physiol Date: 2010-06-03 Impact factor: 4.052
Authors: Antonella Pantaleo; Kristina R Kesely; Maria Carmina Pau; Ioannis Tsamesidis; Evelin Schwarzer; Oleksii A Skorokhod; Huynh D Chien; Marta Ponzi; Lucia Bertuccini; Philip S Low; Francesco M Turrini Journal: Blood Date: 2017-06-20 Impact factor: 22.113
Authors: Stephen P McAdoo; John Reynolds; Gurjeet Bhangal; Jennifer Smith; John P McDaid; Anisha Tanna; William D Jackson; Esteban S Masuda; H Terence Cook; Charles D Pusey; Frederick W K Tam Journal: J Am Soc Nephrol Date: 2014-04-03 Impact factor: 10.121